Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Plasmacytoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1

Interventions

pembrolizumab 3romidepsin 2Specimen Handling 2Melphalan 2Gemcitabine 2Etoposide 2Cyclophosphamide 2Biopsy 210-propargyl-10-deazaaminopterin 2tazemetostat 1talimogene laherparepvec 1prednylidene 1fludarabine 1etoposide phosphate 1durvalumab 1deltacortene 1cc-486 1carmustine, poliferprosan 20 drug combination 1belinostat 1Whole-Body Irradiation 1Triamcinolone 1Tacrolimus 1Prednisone 1Pharmacokinetics 1Pharmacogenomic Variants 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Nivolumab 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, T-Cell × cc-486 × Clear all
NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Celgene

Phase 3 Active not recruiting
93 enrolled 19 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡